| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
ASCOT – old or new drugs for blood pressure?
|
Ritter, James
|
|
2006
|
61 |
3 |
p. 363
|
article
|
| 2 |
Clinically relevant drug interactions with antiepileptic drugs
|
Perucca, Emilio
|
|
2006
|
61 |
3 |
p. 246-255
|
article
|
| 3 |
Curriculum development in pharmacotherapy: testing the ability of preclinical medical students to learn therapeutic problem solving in a randomized controlled trial
|
Vollebregt, J. A.
|
|
2006
|
61 |
3 |
p. 345-351
|
article
|
| 4 |
Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status
|
Uno, Tsukasa
|
|
2006
|
61 |
3 |
p. 309-314
|
article
|
| 5 |
Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids
|
Morrish, Glynn A.
|
|
2006
|
61 |
3 |
p. 326-335
|
article
|
| 6 |
Disposition and pharmacodynamics of propofol during isovolaemic haemorrhage followed by crystalloid resuscitation in humans
|
Takizawa, Eri
|
|
2006
|
61 |
3 |
p. 256-261
|
article
|
| 7 |
Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes
|
Miura, Masatomo
|
|
2006
|
61 |
3 |
p. 315-320
|
article
|
| 8 |
Genetic polymorphisms in KCNQ1, HERG, KCNE1 and KCNE2 genes in the Chinese, Malay and Indian populations of Singapore
|
Koo, Seok Hwee
|
|
2006
|
61 |
3 |
p. 301-308
|
article
|
| 9 |
Hydroxylation of lansoprazole in poor metabolizers of CYP2C19
|
Furuta, Takahisa
|
|
2006
|
61 |
3 |
p. 361
|
article
|
| 10 |
Initial phase of chronic medication use; patients’ reasons for discontinuation
|
Hugtenburg, J. G.
|
|
2006
|
61 |
3 |
p. 352-354
|
article
|
| 11 |
Low incidence of hypertensive disorders of pregnancy in women treated with spiramycin for toxoplasma infection
|
Todros, T.
|
|
2006
|
61 |
3 |
p. 336-340
|
article
|
| 12 |
Orphan drug development is progressing too slowly
|
Joppi, Roberta
|
|
2006
|
61 |
3 |
p. 355-360
|
article
|
| 13 |
Pharmacokinetics of a new testosterone transdermal delivery system, TDS®-testosterone in healthy males
|
Chik, Z.
|
|
2006
|
61 |
3 |
p. 275-279
|
article
|
| 14 |
Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone
|
Simpson, Julie A.
|
|
2006
|
61 |
3 |
p. 289-300
|
article
|
| 15 |
Rare diseases and orphan drugs
|
Aronson, J. K.
|
|
2006
|
61 |
3 |
p. 243-245
|
article
|
| 16 |
Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy
|
Resch, Ulrike
|
|
2006
|
61 |
3 |
p. 262-274
|
article
|
| 17 |
Tadalafil pharmacokinetics in healthy subjects
|
Forgue, S. Thomas
|
|
2006
|
61 |
3 |
p. 280-288
|
article
|
| 18 |
The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia
|
Davies, Benjamin J.
|
|
2006
|
61 |
3 |
p. 321-325
|
article
|
| 19 |
When gatekeepers meet the sentinel: the impact of a prior authorization requirement for cefuroxime on the prescribing behaviour of community-based physicians
|
Kahan, Natan R.
|
|
2006
|
61 |
3 |
p. 341-344
|
article
|
Journal description